Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer

Sven H Loosen, Mark Luedde, Georg Lurje, Martina Spehlmann, Pia Paffenholz, Tom Florian Ulmer, Frank Tacke, Mihael Vucur, Christian Trautwein, Ulf P Neumann, Tom Luedde*, Christoph Roderburg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Pancreatic adenocarcinoma (PDAC) still represents a devastating disease associated with a very limited survival. Novel biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options for individual patients are urgently needed to improve the dismal outcome of PDAC patients. Recently, alterations of Kisspeptin serum levels, a member of the adipokine family, were described in various types of cancers. However, the role of circulating Kisspeptin as a biomarker in PDAC patients is poorly defined. In this study, we measured Kisspeptin serum levels in a cohort of 128 prospectively enrolled PDAC patients undergoing surgical resection as well as 36 healthy controls. Kisspeptin concentrations were elevated in PDAC patients compared to control samples. Nevertheless, Kisspeptin serum levels were independent of tumor-related factors such as the tumor grading, TNM stage, or clinical features such as the ECOG performance status. Finally, in our analysis, neither preoperative nor postoperative Kisspeptin levels turned out as a significant predictor of overall survival after tumor resection. In conclusion, our data suggest that Kisspeptin concentrations are altered in PDAC patients but do not allow to predict patients' outcome after resection of PDAC.

Original languageEnglish
Article number5603474
Pages (from-to)1-8
Number of pages8
JournalDisease Markers
Publication statusPublished - 2019


Dive into the research topics of 'Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this